NovoCure Ltd. (NASDAQ:NVCR)’s share price shot up 3.7% during trading on Friday . The company traded as high as $8.09 and last traded at $8.04, with a volume of 149,998 shares. The stock had previously closed at $7.75.

A number of brokerages have recently commented on NVCR. Deutsche Bank AG dropped their target price on NovoCure from $28.00 to $16.00 and set a “hold” rating for the company in a report on Friday, July 29th. Barclays PLC dropped their target price on NovoCure from $12.00 to $9.00 and set an “underweight” rating for the company in a report on Friday, July 29th. Zacks Investment Research cut NovoCure from a “hold” rating to a “sell” rating in a report on Friday, May 13th. JPMorgan Chase & Co. dropped their target price on NovoCure from $29.00 to $14.00 and set an “overweight” rating for the company in a report on Friday, July 29th. Finally, Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of NovoCure in a report on Tuesday, May 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. NovoCure presently has an average rating of “Hold” and a consensus price target of $21.43.

The stock’s 50-day moving average price is $8.78 and its 200-day moving average price is $11.65. The firm’s market capitalization is $690.48 million.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, July 28th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.11. The business earned $17.90 million during the quarter, compared to the consensus estimate of $15.90 million. On average, equities analysts expect that NovoCure Ltd. will post ($1.74) earnings per share for the current year.

In other NovoCure news, COO Michael J. Ambrogi sold 20,000 shares of the stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $12.24, for a total transaction of $244,800.00. Following the transaction, the chief operating officer now owns 324,084 shares in the company, valued at $3,966,788.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gert L. Perlhagen sold 676,576 shares of the stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $1.85, for a total value of $1,251,665.60. Following the transaction, the director now owns 676,576 shares in the company, valued at approximately $1,251,665.60. The disclosure for this sale can be found here.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.